Lupin announces launch of Formoterol Fumarate Inhalation Solution in the US; stock jumps ~2%

29 Nov 2022 , 12:17 PM

Lupin Limited today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, as a generic equivalent to Mylan Specialty, L.P.’s Perforomist Inhalation Solution, 20 mcg/2 mL.

In the United States, Formoterol Fumarate Inhalation Solution (RLD Perforomist) had an estimated annual sales of USD 268 million, as per the IQVIA MAT September 2022.

Lupin is a Mumbai-based transnational pharmaceutical company in India that focuses on innovation. The Company develops and commercialises a diverse range of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including the United States, India, Asia Pacific (APAC), South Africa, Latin America (LATAM), Europe, and the Middle East.

At around 12.20 PM, Lupin was trading at Rs745.80 up by Rs12.1 or 1.65% from its previous closing of Rs733.70 on the BSE. The scrip touched intraday high and low of Rs759.15 and Rs740.25 respectively.

For feedback and suggestions, write to us at [e-mail]